Literature DB >> 29491161

Relative Abundance of Integrant-Derived Viral RNAs in Infected Tissues Harvested from Chronic Hepatitis B Virus Carriers.

Natalia Freitas1, Tetyana Lukash1, Sumedha Gunewardena2, Benjamin Chappell1, Betty L Slagle3, Severin O Gudima4.   

Abstract

Five matching sets of nonmalignant liver tissues and hepatocellular carcinoma (HCC) samples from individuals chronically infected with hepatitis B virus (HBV) were examined. The HBV genomic sequences were determined by using overlapping PCR amplicons covering the entire viral genome. Four pairs of tissues were infected with HBV genotype C, while one pair was infected with HBV genotype B. HBV replication markers were found in all tissues. In the majority of HCC samples, the levels of pregenomic/precore RNA (pgRNA) and covalently closed circular DNA (cccDNA) were lower than those in liver tissue counterparts. Regardless of the presence of HBV replication markers, (i) integrant-derived HBV RNAs (id-RNAs) were found in all tissues by reverse transcription-PCR (RT-PCR) analysis and were considerably abundant or predominant in 6/10 tissue samples (2 liver and 4 HCC samples), (ii) RNAs that were polyadenylated using the cryptic HBV polyadenylation signal and therefore could be produced by HBV replication or derived from integrated HBV DNA were found in 5/10 samples (3 liver and 2 HCC samples) and were considerably abundant species in 3/10 tissues (2 livers and 1 HCC), and (iii) cccDNA-transcribed RNAs polyadenylated near position 1931 were not abundant in 7/10 tissues (2 liver and 5 HCC samples) and were predominant in only two liver samples. Subsequent RNA sequencing analysis of selected liver/HCC samples also showed relative abundance of id-RNAs in most of the examined tissues. Our findings suggesting that id-RNAs could represent a significant source of HBV envelope proteins, which is independent of viral replication, are discussed in the context of the possible contribution of id-RNAs to the HBV life cycle.IMPORTANCE The relative abundance of integrant-derived HBV RNAs (id-RNAs) in chronically infected tissues suggest that id-RNAs coding for the envelope proteins may facilitate the production of a considerable fraction of surface antigens (HBsAg) in infected cells bearing HBV integrants. If the same cells support HBV replication, then a significant fraction of assembled HBV virions could bear id-RNA-derived HBsAg as a major component of their envelopes. Therefore, the infectivity of these HBV virions and their ability to facilitate virus cell-to-cell spread could be determined mainly by the properties of id-RNA-derived envelope proteins and not by the properties of replication-derived HBsAg. These interpretations suggest that id-RNAs may play a role in the maintenance of chronic HBV infection and therefore contribute to the HBV life cycle. Furthermore, the production of HBsAg from id-RNAs independently of viral replication may explain at least in part why treatment with interferon or nucleos(t)ides in most cases fails to achieve a loss of serum HBsAg.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  HBV life cycle; chronic HBV infection; hepatitis B virus; integrant-derived viral RNAs

Mesh:

Substances:

Year:  2018        PMID: 29491161      PMCID: PMC5923063          DOI: 10.1128/JVI.02221-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  91 in total

Review 1.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

Review 2.  Heterogeneity in mammalian RNA 3' end formation.

Authors:  Joel R Neilson; Rickard Sandberg
Journal:  Exp Cell Res       Date:  2010-03-06       Impact factor: 3.905

3.  Frequent loss of chromosome 8p in hepatitis B virus-positive hepatocellular carcinomas from China.

Authors:  S A Becker; Y Z Zhou; B L Slagle
Journal:  Cancer Res       Date:  1996-11-01       Impact factor: 12.701

4.  Comparison study on the complete sequence of hepatitis B virus identifies new mutations in core gene associated with hepatocellular carcinoma.

Authors:  Yu Zhu; Yan Jin; Xia Guo; Xin Bai; Taoyang Chen; Jinbing Wang; Gengsun Qian; John D Groopman; Jianren Gu; Jinjun Li; Hong Tu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08-10       Impact factor: 4.254

Review 5.  Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications.

Authors:  Teresa Pollicino; Irene Cacciola; Francesca Saffioti; Giovanni Raimondo
Journal:  J Hepatol       Date:  2014-05-05       Impact factor: 25.083

6.  Detection of clonally expanded hepatocytes in chimpanzees with chronic hepatitis B virus infection.

Authors:  William S Mason; Huey-Chi Low; Chunxiao Xu; Carol E Aldrich; Catherine A Scougall; Arend Grosse; Andrew Clouston; Deborah Chavez; Samuel Litwin; Suraj Peri; Allison R Jilbert; Robert E Lanford
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

7.  Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype.

Authors:  Erin Connolly; Margherita Melegari; Pablo Landgraf; Tatyana Tchaikovskaya; Bud C Tennant; Betty L Slagle; Leslie E Rogler; Mihaela Zavolan; Thomas Tuschl; Charles E Rogler
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

8.  Hepatitis delta virus infects the cells of hepadnavirus-induced hepatocellular carcinoma in woodchucks.

Authors:  Natalia Freitas; Jessica Salisse; Celso Cunha; Ilia Toshkov; Stephan Menne; Severin O Gudima
Journal:  Hepatology       Date:  2012-04-25       Impact factor: 17.425

9.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

10.  Genomic and transcriptome profiling identified both human and HBV genetic variations and their interactions in Chinese hepatocellular carcinoma.

Authors:  Hua Dong; Ziliang Qian; Lan Zhang; Yunqin Chen; Zhenggang Ren; Qunsheng Ji
Journal:  Genom Data       Date:  2015-07-22
View more
  7 in total

Review 1.  Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure.

Authors:  Andrew Vaillant
Journal:  Viruses       Date:  2021-04-23       Impact factor: 5.048

2.  Generation and characterization of a stable cell line persistently replicating and secreting the human hepatitis delta virus.

Authors:  Yi Ni; Zhenfeng Zhang; Lisa Engelskircher; Georg Verch; Thomas Tu; Florian A Lempp; Stephan Urban
Journal:  Sci Rep       Date:  2019-07-10       Impact factor: 4.379

Review 3.  A review on hepatitis D: From virology to new therapies.

Authors:  Nathalie Mentha; Sophie Clément; Francesco Negro; Dulce Alfaiate
Journal:  J Adv Res       Date:  2019-03-29       Impact factor: 10.479

Review 4.  Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure.

Authors:  Romina Salpini; Stefano D'Anna; Livia Benedetti; Lorenzo Piermatteo; Upkar Gill; Valentina Svicher; Patrick T F Kennedy
Journal:  Front Microbiol       Date:  2022-09-02       Impact factor: 6.064

5.  Functional cure of hepatitis B requires silencing covalently closed circular and integrated hepatitis B virus DNA.

Authors:  Marc G Ghany; Anna S Lok
Journal:  J Clin Invest       Date:  2022-09-15       Impact factor: 19.456

6.  Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss.

Authors:  I-Chin Wu; Wen-Chun Liu; Yen-Cheng Chiu; Hung-Chih Chiu; Pin-Nan Cheng; Ting-Tsung Chang
Journal:  Microorganisms       Date:  2021-05-26

7.  Efficient silencing of hepatitis B virus S gene through CRISPR-mediated base editing.

Authors:  Hao Zhou; Xiaomei Wang; Clifford J Steer; Guisheng Song; Junqi Niu
Journal:  Hepatol Commun       Date:  2022-03-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.